0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Research Report 2026
Published Date: 2026-02-03
|
Report Code: QYRE-Auto-34J18257
Home | Market Reports | Health| Pharmacy
Global Human Granulocyte Macrophage Colony stimulating Factor for Injection Market Research Report 2024
BUY CHAPTERS

Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Research Report 2026

Code: QYRE-Auto-34J18257
Report
2026-02-03
Pages:109
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market

The global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Human Granulocyte/Macrophage Colony-stimulating Factor for Injection competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection (GM-CSF) is a recombinant protein that stimulates the production, differentiation, and activation of both granulocytes (such as neutrophils) and macrophages, which are crucial components of the immune system. Clinically, GM-CSF is used to accelerate white blood cell recovery in patients undergoing chemotherapy, bone marrow transplantation, or other treatments that suppress immune function. Additionally, GM-CSF is sometimes applied in immunotherapy protocols to boost immune activity against infections or certain cancers.
The North American market for Human Granulocyte/Macrophage Colony-stimulating Factor for Injection is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Human Granulocyte/Macrophage Colony-stimulating Factor for Injection is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection include Partner Therapeutics, Changchun GeneScience Pharmaceutical, North China Pharmaceutical, Amoytop Biotech, Hainan Unipul Pharmaceutical, Harbin Pharmaceutical Group, Guangzhou Baiyunshan Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Human Granulocyte/Macrophage Colony-stimulating Factor for Injection. The Human Granulocyte/Macrophage Colony-stimulating Factor for Injection market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Human Granulocyte/Macrophage Colony-stimulating Factor for Injection manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Report

Report Metric Details
Report Name Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market
Segment by Type
  • Subcutaneous Injection
  • Intravenous Injection
by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Partner Therapeutics, Changchun GeneScience Pharmaceutical, North China Pharmaceutical, Amoytop Biotech, Hainan Unipul Pharmaceutical, Harbin Pharmaceutical Group, Guangzhou Baiyunshan Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Human Granulocyte/Macrophage Colony-stimulating Factor for Injection manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Human Granulocyte/Macrophage Colony-stimulating Factor for Injection sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market report?

Ans: The main players in the Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market are Partner Therapeutics, Changchun GeneScience Pharmaceutical, North China Pharmaceutical, Amoytop Biotech, Hainan Unipul Pharmaceutical, Harbin Pharmaceutical Group, Guangzhou Baiyunshan Pharmaceutical

What are the Application segmentation covered in the Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market report?

Ans: The Applications covered in the Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market report?

Ans: The Types covered in the Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market report are Subcutaneous Injection, Intravenous Injection

1 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Overview
1.1 Product Definition
1.2 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection by Type
1.2.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Value by Type: 2025 vs 2032
1.2.2 Subcutaneous Injection
1.2.3 Intravenous Injection
1.3 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection by Application
1.3.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size Estimates and Forecasts
1.4.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue 2021–2032
1.4.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales 2021–2032
1.4.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Competition by Manufacturers
2.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Manufacturers (2021–2026)
2.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection, Product Types and Applications
2.7 Global Key Manufacturers of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection, Date of Entry into the Industry
2.8 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Competitive Situation and Trends
2.8.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Players Market Share by Revenue
2.8.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Scenario by Region
3.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Region: 2021–2032
3.2.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Region: 2021–2026
3.2.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Region: 2027–2032
3.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Region: 2021–2032
3.3.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Region: 2021–2026
3.3.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Region: 2027–2032
3.4 North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Facts & Figures by Country
3.4.1 North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (2021–2032)
3.4.3 North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Facts & Figures by Country
3.5.1 Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (2021–2032)
3.5.3 Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Facts & Figures by Region
3.6.1 Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Region (2021–2032)
3.6.3 Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Facts & Figures by Country
3.7.1 Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (2021–2032)
3.7.3 Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (2021–2032)
3.8.3 Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Type (2021–2032)
4.1.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Type (2021–2026)
4.1.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Type (2027–2032)
4.1.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Type (2021–2032)
4.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Type (2021–2032)
4.2.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Type (2021–2026)
4.2.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Type (2027–2032)
4.2.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Type (2021–2032)
4.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Price by Type (2021–2032)
5 Segment by Application
5.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Application (2021–2032)
5.1.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Application (2021–2026)
5.1.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Application (2027–2032)
5.1.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Application (2021–2032)
5.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Application (2021–2032)
5.2.1 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Application (2021–2026)
5.2.2 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Application (2027–2032)
5.2.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Application (2021–2032)
5.3 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Partner Therapeutics
6.1.1 Partner Therapeutics Company Information
6.1.2 Partner Therapeutics Description and Business Overview
6.1.3 Partner Therapeutics Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Partner Therapeutics Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product Portfolio
6.1.5 Partner Therapeutics Recent Developments/Updates
6.2 Changchun GeneScience Pharmaceutical
6.2.1 Changchun GeneScience Pharmaceutical Company Information
6.2.2 Changchun GeneScience Pharmaceutical Description and Business Overview
6.2.3 Changchun GeneScience Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Changchun GeneScience Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product Portfolio
6.2.5 Changchun GeneScience Pharmaceutical Recent Developments/Updates
6.3 North China Pharmaceutical
6.3.1 North China Pharmaceutical Company Information
6.3.2 North China Pharmaceutical Description and Business Overview
6.3.3 North China Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 North China Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product Portfolio
6.3.5 North China Pharmaceutical Recent Developments/Updates
6.4 Amoytop Biotech
6.4.1 Amoytop Biotech Company Information
6.4.2 Amoytop Biotech Description and Business Overview
6.4.3 Amoytop Biotech Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Amoytop Biotech Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product Portfolio
6.4.5 Amoytop Biotech Recent Developments/Updates
6.5 Hainan Unipul Pharmaceutical
6.5.1 Hainan Unipul Pharmaceutical Company Information
6.5.2 Hainan Unipul Pharmaceutical Description and Business Overview
6.5.3 Hainan Unipul Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Hainan Unipul Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product Portfolio
6.5.5 Hainan Unipul Pharmaceutical Recent Developments/Updates
6.6 Harbin Pharmaceutical Group
6.6.1 Harbin Pharmaceutical Group Company Information
6.6.2 Harbin Pharmaceutical Group Description and Business Overview
6.6.3 Harbin Pharmaceutical Group Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Harbin Pharmaceutical Group Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product Portfolio
6.6.5 Harbin Pharmaceutical Group Recent Developments/Updates
6.7 Guangzhou Baiyunshan Pharmaceutical
6.7.1 Guangzhou Baiyunshan Pharmaceutical Company Information
6.7.2 Guangzhou Baiyunshan Pharmaceutical Description and Business Overview
6.7.3 Guangzhou Baiyunshan Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Guangzhou Baiyunshan Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product Portfolio
6.7.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Industry Chain Analysis
7.2 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Production Mode & Process Analysis
7.4 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales and Marketing
7.4.1 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Channels
7.4.2 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Distributors
7.5 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Customer Analysis
8 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Dynamics
8.1 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Industry Trends
8.2 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Drivers
8.3 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Challenges
8.4 Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection, Product Types and Applications
 Table 12. Global Key Manufacturers of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Companies by Tier (Tier 1, Tier 2, Tier 3), based on Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Region (K Units), 2021–2026
 Table 18. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Region (2021–2026)
 Table 19. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Region (K Units), 2027–2032
 Table 20. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Region (2027–2032)
 Table 21. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Region (2021–2026)
 Table 23. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Region (2027–2032)
 Table 25. North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (K Units), 2021–2026
 Table 27. North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (K Units), 2027–2032
 Table 28. North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (K Units), 2021–2026
 Table 32. Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (K Units), 2027–2032
 Table 33. Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (K Units), 2021–2026
 Table 42. Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (K Units), 2027–2032
 Table 43. Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units) by Type (2021–2026)
 Table 51. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units) by Type (2027–2032)
 Table 52. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Type (2021–2026)
 Table 53. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Type (2027–2032)
 Table 54. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Type (2021–2026)
 Table 57. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Type (2027–2032)
 Table 58. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units) by Application (2021–2026)
 Table 61. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units) by Application (2027–2032)
 Table 62. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Application (2021–2026)
 Table 63. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Application (2027–2032)
 Table 64. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Application (2021–2026)
 Table 67. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Application (2027–2032)
 Table 68. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Price (US$/Unit) by Application (2027–2032)
 Table 70. Partner Therapeutics Company Information
 Table 71. Partner Therapeutics Description and Business Overview
 Table 72. Partner Therapeutics Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Partner Therapeutics Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product
 Table 74. Partner Therapeutics Recent Developments/Updates
 Table 75. Changchun GeneScience Pharmaceutical Company Information
 Table 76. Changchun GeneScience Pharmaceutical Description and Business Overview
 Table 77. Changchun GeneScience Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Changchun GeneScience Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product
 Table 79. Changchun GeneScience Pharmaceutical Recent Developments/Updates
 Table 80. North China Pharmaceutical Company Information
 Table 81. North China Pharmaceutical Description and Business Overview
 Table 82. North China Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. North China Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product
 Table 84. North China Pharmaceutical Recent Developments/Updates
 Table 85. Amoytop Biotech Company Information
 Table 86. Amoytop Biotech Description and Business Overview
 Table 87. Amoytop Biotech Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Amoytop Biotech Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product
 Table 89. Amoytop Biotech Recent Developments/Updates
 Table 90. Hainan Unipul Pharmaceutical Company Information
 Table 91. Hainan Unipul Pharmaceutical Description and Business Overview
 Table 92. Hainan Unipul Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Hainan Unipul Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product
 Table 94. Hainan Unipul Pharmaceutical Recent Developments/Updates
 Table 95. Harbin Pharmaceutical Group Company Information
 Table 96. Harbin Pharmaceutical Group Description and Business Overview
 Table 97. Harbin Pharmaceutical Group Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Harbin Pharmaceutical Group Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product
 Table 99. Harbin Pharmaceutical Group Recent Developments/Updates
 Table 100. Guangzhou Baiyunshan Pharmaceutical Company Information
 Table 101. Guangzhou Baiyunshan Pharmaceutical Description and Business Overview
 Table 102. Guangzhou Baiyunshan Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Guangzhou Baiyunshan Pharmaceutical Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Product
 Table 104. Guangzhou Baiyunshan Pharmaceutical Recent Developments/Updates
 Table 105. Key Raw Materials Lists
 Table 106. Raw Materials Key Suppliers Lists
 Table 107. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Distributors List
 Table 108. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Customers List
 Table 109. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Trends
 Table 110. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Drivers
 Table 111. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Challenges
 Table 112. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources
 Table 116. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection
 Figure 2. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Share by Type: 2025 & 2032
 Figure 4. Subcutaneous Injection Product Picture
 Figure 5. Intravenous Injection Product Picture
 Figure 6. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Share by Application: 2025 & 2032
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Other
 Figure 11. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size (US$ Million), 2021–2032
 Figure 13. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales (K Units), 2021–2032
 Figure 14. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Average Price (US$/Unit), 2021–2032
 Figure 15. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Report Years Considered
 Figure 16. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Share by Manufacturers in 2025
 Figure 17. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Players: Market Share by Revenue in Human Granulocyte/Macrophage Colony-stimulating Factor for Injection in 2025
 Figure 19. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Country (2021–2032)
 Figure 22. North America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Country (2021–2032)
 Figure 23. United States Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Country (2021–2032)
 Figure 26. Europe Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Country (2021–2032)
 Figure 27. Germany Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Region (2021–2032)
 Figure 34. China Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. China Taiwan Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Southeast Asia Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Country (2021–2032)
 Figure 42. Latin America Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Country (2021–2032)
 Figure 43. Mexico Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Brazil Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Argentina Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Colombia Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection by Type (2021–2032)
 Figure 53. Global Revenue Market Share of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection by Type (2021–2032)
 Figure 54. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Price (US$/Unit) by Type (2021–2032)
 Figure 55. Global Sales Market Share of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection by Application (2021–2032)
 Figure 56. Global Revenue Market Share of Human Granulocyte/Macrophage Colony-stimulating Factor for Injection by Application (2021–2032)
 Figure 57. Global Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Price (US$/Unit) by Application (2021–2032)
 Figure 58. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS